- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02878096
Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study
An Open-Label, 2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1404 Administered to Healthy Male Subjects
The primary objectives of the study are:
- To determine the absolute bioavailability of SK-1404
- To assess the mass balance recovery after a single oral (PO) dose of carbon-14 (14C)-SK-1404
- To provide plasma, urine and faecal samples for metabolite profiling and structural identification
The secondary objectives of the study are:
- To determine the routes and rates of elimination of [14C]-SK-1404
- To identify the chemical structure of each metabolite with an exposure (AUC) of more than 10% of circulating total radioactivity
- To explore the intravenous (IV) pharmacokinetics (PK) of [14C]-SK-1404
- To further explore the PO PK of SK-1404
- To provide additional safety and tolerability information for SK-1404
Studie Overzicht
Gedetailleerde beschrijving
This is a single-centre, 2-part, open-label, non-randomised, sequential, single dose study in healthy male subjects. It is planned to enrol a single cohort of 6 healthy male subjects who will participate in Parts 1 and Part 2 of the study.
In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
In Part 2, each subject will receive a single PO dose of [14C]-SK-1404.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Nottingham
-
Ruddington, Nottingham, Verenigd Koninkrijk, NG11 6JS
- Quotient Clinical
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Healthy males
- Age 30 to 65 years of age
- Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
- Must be willing and able to communicate and participate in the whole study
- Must provide written informed consent
- Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day)
- Must agree to use an adequate method of contraception
Exclusion Criteria:
- Males with pregnant partners
- Participation in a clinical research study within the 3 months prior to IMP dose
- Subjects who are study site employees, or immediate family members of a study site or sponsor employee
- Subjects who have previously been enrolled in this study
- Subjects who have previously been dosed with SK-1404
- History of any drug or alcohol abuse in the past 2 years
- Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) in the past year
- Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide reading of greater than 10 ppm at screening or admission
- Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
- Subjects who have been enrolled in an ADME study in the last 12 months
- Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
- Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1)
- Aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase >1.5 × upper limit of normal confirmed by repeat testing
- Serum sodium below the lower limit of normal
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: [14C]-SK-1404
|
In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Absolute bioavailability (F) calculated with the AUC values of IV administration in Part 1 and PO administration in Part 2
Tijdsspanne: Predose to 96hr
|
Predose to 96hr
|
|
Mass balance recovery of total radioactivity in urine, faeces and all excreta
Tijdsspanne: Predose to 168hr
|
Amount excreted (Ae), and Ae as a percentage of the administered dose (%Ae), cumulative recovery (Cum Ae) and cumulative recovery expressed as a percentage of the dose (Cum %Ae)
|
Predose to 168hr
|
Number and structural identification of known and unknown metabolites of SK-1404 in the plasma, urine and faeces samples
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
|
%Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
|
Cum Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
|
Cum %Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
|
Cum Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
|
Cum %Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
|
Number and structural identification of unknown metabolites of SK-1404 with an AUC of more than 10% of circulating total radioactivity
Tijdsspanne: Predose to 168hr
|
Predose to 168hr
|
|
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The apparent volume of distribution (Vd) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The apparent volume of distribution (Vss) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Tijdsspanne: Predose to 96hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 96hr
|
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The absolute bioavailability (F, PO vs IV from Part 1) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The apparent volume of distribution (Vd/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Tijdsspanne: Predose to 168hr
|
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
|
Predose to 168hr
|
To collect further information about the safety and tolerability of IMP
Tijdsspanne: Predose to 168hr
|
By assessing physical examination, safety laboratory tests, vital signs, electrocardiograms (ECGs) and AEs.
|
Predose to 168hr
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Litza McKenzie, MBChB BScMedSci, Quotient Clinical
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- QCL117764
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Nachtelijk
-
Seoul National University HospitalVoltooidPatiënten bij wie het urinevolume 's nachts meer dan een derde van het totale dagelijkse urinevolume (NPU) had en meer dan twee keer 's nachts werd geplast (Nocturia)Korea, republiek van
Klinische onderzoeken op [14C]-SK-1404
-
Sanwa Kagaku Kenkyusho Co., Ltd.VoltooidNocturie Door nachtelijke polyurieJapan
-
Sanwa Kagaku Kenkyusho Co., Ltd.Voltooid
-
Molecular Insight Pharmaceuticals, Inc.VoltooidProstaatkankerVerenigde Staten, België, Italië, Tsjechische Republiek, Hongarije, Nederland, Polen, Russische Federatie
-
Molecular Insight Pharmaceuticals, Inc.Voltooid
-
Molecular Insight Pharmaceuticals, Inc.Voltooid
-
Molecular Insight Pharmaceuticals, Inc.VoltooidProstaatkankerVerenigde Staten
-
Molecular Insight Pharmaceuticals, Inc.VoltooidProstaatkankerVerenigde Staten, Canada
-
Molecular Insight Pharmaceuticals, Inc.VoltooidProstaatkankerVerenigde Staten
-
Cellectar, IncVoltooidVaste tumorenVerenigde Staten
-
Indivior Inc.VoltooidOpioïdengebruiksstoornisVerenigde Staten